000163994 001__ 163994
000163994 005__ 20240229133511.0
000163994 0247_ $$2doi$$a10.1007/s00106-020-00955-5
000163994 0247_ $$2pmid$$apmid:33048200
000163994 0247_ $$2ISSN$$a0017-6192
000163994 0247_ $$2ISSN$$a1433-0458
000163994 037__ $$aDKFZ-2020-02194
000163994 041__ $$ager
000163994 082__ $$a610
000163994 1001_ $$0P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aRühle, Alexander$$b0$$eFirst author
000163994 245__ $$aDe-escalation concepts for chemoradiotherapy of HPV-positive oropharyngeal carcinomas: pros and cons[Deeskalationsstrategien für die Radiochemotherapie HPV-positiver Oropharynxkarzinome: Pro und Kontra].
000163994 260__ $$aNew York$$bSpringer$$c2021
000163994 3367_ $$2DRIVER$$aarticle
000163994 3367_ $$2DataCite$$aOutput Types/Journal article
000163994 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1675086785_31442$$xReview Article
000163994 3367_ $$2BibTeX$$aARTICLE
000163994 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163994 3367_ $$00$$2EndNote$$aJournal Article
000163994 500__ $$a2021 Apr;69(4):278-284
000163994 520__ $$aIn contrast to alcohol- and nicotine-induced head and neck tumors, human papillomavirus (HPV)-positive oropharyngeal carcinoma rather affects younger patients, and the incidence of this entity is continuously increasing. Due to the significantly better prognosis of HPV-positive oropharyngeal carcinoma, various treatment de-escalation strategies are currently being investigated, with the aim of reducing toxicity without affecting the good survival rates of these patients.This study aims to evaluate the evidence for treatment de-escalation in HPV-positive oropharyngeal carcinoma.A literature search was performed and relevant studies are critically discussed.De-escalation strategies for HPV-associated oropharyngeal carcinoma using induction chemotherapy or radiation dose reduction have demonstrated good oncological results in phase II trials, with lower toxicity rates compared to historical controls. However, both of the first published phase III trials investigating de-escalation of concomitant chemotherapy regimens demonstrated inferior outcomes for the deescalated treatment strategies without improvements in treatment-associated toxicities. Additional phase-III trials investigating other de-escalation strategies have not yet been published.Treatment de-escalation should be performed exclusively in prospective studies and can currently not be recommended in clinical routine.
000163994 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000163994 588__ $$aDataset connected to CrossRef, PubMed,
000163994 7001_ $$0P:(DE-HGF)0$$aNicolay, N. H.$$b1$$eLast author
000163994 773__ $$0PERI:(DE-600)1459183-2$$a10.1007/s00106-020-00955-5$$n4$$p278-284$$tHNO$$v69$$x1433-0458$$y2021
000163994 909CO $$ooai:inrepo02.dkfz.de:163994$$pVDB
000163994 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000163994 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000163994 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000163994 9130_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000163994 9141_ $$y2021
000163994 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2019-12-20$$wger
000163994 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2019-12-20$$wger
000163994 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2019-12-20
000163994 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2019-12-20
000163994 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2019-12-20
000163994 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2019-12-20
000163994 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2019-12-20
000163994 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2019-12-20
000163994 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2019-12-20
000163994 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2019-12-20
000163994 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHNO : 2018$$d2019-12-20
000163994 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2019-12-20
000163994 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x0
000163994 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x1
000163994 980__ $$ajournal
000163994 980__ $$aVDB
000163994 980__ $$aI:(DE-He78)FR01-20160331
000163994 980__ $$aI:(DE-He78)E055-20160331
000163994 980__ $$aUNRESTRICTED